Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)

NCT04626674 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.

NCT NCT04626674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04626674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
Lead sponsor
Sarepta Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 23, 2020
Completion date
February 29, 2028
Enrollment
83 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy